Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its new generation fully biodegradable and absorbable cardiac stent. This innovation marks a significant advancement in the field of interventional cardiology.
The stent is the world’s first targeted absorbable stent designed with a thickness comparable to that of metal stents, without compromising strength. It incorporates a unique targeted elution technology that minimizes effective drug loading while maintaining equivalent efficacy. This breakthrough provides coronary heart disease patients with a novel treatment option that offers the potential for better long-term outcomes.
The FUTURE studies, which are large-scale clinical trials, have demonstrated the safety and efficacy of the fire stent. With a two-year follow-up, the incidence of thrombosis in patients using the stent was a mere 0.32%, and impressively, the four-year thrombotic event rate stood at 0% in randomized controlled trials (RCTs), underscoring the product’s reliability and safety profile.- Flcube.com
